Contact
Please use this form to send email to PR contact of this press release:
Coherus Announces CHS-1701 (Neulasta® Biosimilar) Met Both Primary Endpoints in Registration-Enabling Immunogenicity Study
TO:
Please use this form to send email to PR contact of this press release:
Coherus Announces CHS-1701 (Neulasta® Biosimilar) Met Both Primary Endpoints in Registration-Enabling Immunogenicity Study
TO: